About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Psoriasis Clinical Trials in Houston | 209 Studies | Clareo Health

Clinical Trials PsoriasisHouston

Psoriasis Clinical Trials in Houston

Find 209 clinical trials for psoriasis near Houston, Texas. Connect with research centers in your area.

All Psoriasis trials nationwide All trials in Houston

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 121-140 of 209 trials

COMPLETEDPhase 2< 1 mile

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

NCT02785185

A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study.

Bausch Health Americas, Inc.150 participantsStarted Jun 2016

Rogers, Arkansas, United States • Beverly Hills, California, United States • Carlsbad, California, United States +10 more locations

COMPLETEDPhase 3< 1 mile

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

NCT02462122

Safety and Efficacy of IDP-118 in the treatment of plaque psoriasis

Plaque Psoriasis

Bausch Health Americas, Inc.215 participantsStarted Aug 2015

Fremont, California, United States • Boynton Beach, Florida, United States • North Miami Beach, Florida, United States +13 more locations

Psoriasis Trials in Other Cities

New York Los Angeles Chicago Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

COMPLETEDPhase 1/2< 1 mile

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis

NCT03630939

This is a multicenter, double-blind, randomized, vehicle-controlled, parallel-group proof-of-concept study designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of topically applied ESR-114 following twice daily (BID) application for 42 days (6 weeks).

Psoriatic Plaque

Escalier Biosciences B.V.104 participantsStarted Aug 2018

Santa Monica, California, United States • Tampa, Florida, United States • Fridley, Minnesota, United States +7 more locations

COMPLETEDPhase 4< 1 mile

A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis

NCT03573323

The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.

Plaque Psoriasis

Eli Lilly and Company1,027 participantsStarted Nov 2018

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Phoenix, Arizona, United States +121 more locations

COMPLETEDPhase 3< 1 mile

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01172938

The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis, specifically in improving signs and symptoms of psoriatic arthritis (tender and swollen joints, pain, physical function) in treated patients.

Psoriatic Arthritis

Amgen504 participantsStarted Jun 2010

Birmingham, Alabama, United States • Phoenix, Arizona, United States • La Jolla, California, United States +89 more locations

COMPLETEDPhase 3< 1 mile

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

NCT02513550

The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.

Plaque Psoriasis

Eli Lilly and Company1,257 participantsStarted Aug 2015

Birmingham, Alabama, United States • Anaheim, California, United States • Beverly Hills, California, United States +122 more locations

COMPLETEDPhase 4< 1 mile

Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast

NCT02749370

To evaluate the efficacy of etanercept in adults with moderate to severe plaque psoriasis who have failed therapy with apremilast (Otezla).

Plaque Psoriasis

Amgen80 participantsStarted May 2016

Scottsdale, Arizona, United States • Beverly Hills, California, United States • Fountain Valley, California, United States +19 more locations

COMPLETEDPhase 3< 1 mile

Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis

NCT01925768

The purpose of this study is to determine whether apremilast is safe and effective for treating patients with psoriatic arthritis.

Psoriatic Arthritis

Amgen219 participantsStarted Sep 2013

Birmingham, Alabama, United States • Palm Desert, California, United States • Brandon, Florida, United States +68 more locations

COMPLETEDPhase 3< 1 mile

PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01212770

The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis and a qualifying psoriasis lesion. Apremilast is proposed to improve signs and symptoms of psoriatic arthritis (tender and swollen joints, pain, physical function) in treated patients.

Psoriatic Arthritis

Amgen505 participantsStarted Sep 2010

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +88 more locations

COMPLETEDPhase 3< 1 mile

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

NCT02515097

This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).

Plaque Psoriasis

Bausch Health Americas, Inc.213 participantsStarted Nov 2015

Santa Ana, California, United States • Boynton Beach, Florida, United States • Clearwater, Florida, United States +12 more locations

COMPLETEDPhase 219 miles

Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis

NCT02785172

Safety and Efficacy of IDP-118 Lotion to Ultravate® Cream, in the Treatment of Plaque Psoriasis

Bausch Health Americas, Inc.154 participantsStarted Apr 2016

Fullerton, California, United States • La Mesa, California, United States • San Diego, California, United States +11 more locations

COMPLETEDPhase 322 miles

LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris

NCT02899962

A phase 3 trial comparing the efficacy and safety of LEO 90100 aerosol foam with the aerosol foam vehicle used twice weekly as long-term maintenance therapy in subjects with psoriasis vulgaris. A 12-month, international, multi-centre, randomised, vehicle controlled, double-blind, 2-arm, parallel group trial.

Psoriasis Vulgaris

LEO Pharma722 participantsStarted Feb 2017

Fremont, California, United States • Santa Monica, California, United States • Denver, Colorado, United States +55 more locations

COMPLETEDPhase 322 miles

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

NCT03731091

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd) to the Marketed Product Enstilar® Foam (LEO Pharma Inc.) in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis)

Psoriasis Vulgaris

Glenmark Pharmaceuticals Ltd. India494 participantsStarted Oct 2018

Encinitas, California, United States • Fountain Valley, California, United States • San Diego, California, United States +27 more locations

COMPLETEDPhase 322 miles

A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

NCT03123471

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis of the scalp. Approximately 300 subjects with moderate to severe plaque psoriasis of the scalp will be randomized 2:1 to receive either apremilast 30 mg twice daily (BID) or placebo for the first 16 weeks.

Amgen303 participantsStarted May 2017

Rogers, Arkansas, United States • Fountain Valley, California, United States • Los Angeles, California, United States +42 more locations

COMPLETEDPhase 3146 miles

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

NCT03731052

This Phase 3 study (Study 307) has been designed to determine and compare the efficacy and safety of 188-0551 Spray and Vehicle Spray applied twice daily for up to four weeks in subjects with plaque psoriasis. Subjects will be instructed to apply the test article (188-0551 Spray or Vehicle Spray) to all psoriasis plaques within the designated Treatment Area twice daily for four weeks (Study Day 29), unless the investigator verifies the subject's psoriasis has cleared at Day 15, then test article application will be for 2 weeks (Study Day 15).

Plaque Psoriasis

Therapeutics, Inc.217 participantsStarted Oct 2018

Los Angeles, California, United States • Ocala, Florida, United States • Macon, Georgia, United States +11 more locations

COMPLETEDPhase 3163 miles

Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

NCT02024646

The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16. The safety objective of this study is to evaluate the safety profile of brodalumab in subjects with psoriatic arthritis.

Psoriatic Arthritis

Bausch Health Americas, Inc.484 participantsStarted Mar 2014

Peoria, Arizona, United States • Little Rock, Arkansas, United States • Cypress, California, United States +100 more locations

COMPLETEDPhase 3214 miles

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis

NCT02404350

The purpose of this study was to demonstrate efficacy including effect on inhibition of progression of structural damage, safety and tolerability up to 2 years with primary focus at Week 16 (week 24 for structural damage), to support the use of secukinumab pre-filled syringe (PFS) by subcutaneous (s.c.) self-administration with or without loading regimen in subjects with active Psoriatic Arthritis (PsA) despite current or previous NSAID, DMARD therapy and/or previous anti-TNFα therapy. Long term efficacy up to 2 years was based on signs and symptoms of joint/bone structure preservation (X-ray) and improvement in physical function measured by Health Assessment Questionnaire - Disability Index (HAQ-DI©), as well as skin and nail improvement for psoriasis signs.

Psoriatic Arthritis

Novartis Pharmaceuticals997 participantsStarted Aug 2015

Upland, California, United States • Aurora, Colorado, United States • Denver, Colorado, United States +169 more locations

TERMINATEDPhase 2254 miles

AMG 827 in Subjects With Psoriatic Arthritis

NCT01516957

The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis

Psoriatic Arthritis

Bausch Health Americas, Inc.168 participantsStarted Oct 2011

Peoria, Arizona, United States • Scottsdale, Arizona, United States • Tucson, Arizona, United States +28 more locations

COMPLETEDPhase 3313 miles

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis

NCT03759197

This Phase 3 study (Study 305) has been designed to determine and compare the efficacy and safety of 188-0551 Spray and Vehicle Spray applied twice daily for up to four weeks in subjects with plaque psoriasis. Subjects will be instructed to apply the test article (188-0551 Spray or Vehicle Spray) to all psoriasis plaques within the designated Treatment Area twice daily for four weeks (Study Day 29), unless the investigator verifies the subject's psoriasis has cleared at Day 15, then test article application will be for 2 weeks (Study Day 15).

Plaque Psoriasis

Therapeutics, Inc.206 participantsStarted Nov 2018

Fort Smith, Arkansas, United States • Fountain Valley, California, United States • Fremont, California, United States +9 more locations

COMPLETED1105 miles

Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade

NCT02605642

To assess persistence of CT-P13 in patients with Rheumatoid Diseases (Rheumatoid arthritis \[RA\], ankylosing spondylitis \[AS\], and psoriatic arthritis \[PsA\]) who are naïve to biologics or are switching from stable Remicade to CT-P13. The main objectives of the study are: * To evaluate real-life drug persistence in RA, AS, and PsA patients who are either initiated with CT-P13 as their first biologic, or who are switched from stable Remicade * To characterise the patient populations and drug usage patterns of RA, AS, and PsA patients who are either initiated with CT-P13 as their first biologic, or who are switched from stable Remicade * To assess the safety of CT-P13 in RA, AS, and PsA patients who are either initiated with CT-P13 as their first biologic, or who are switched from stable Remicade for up to 2 years

Rheumatoid DiseasesRheumatoid ArthritisAnkylosing Spondylitis+1 more

Pfizer351 participantsStarted Sep 2015

Plovdiv, Bulgaria • Plovdiv, Bulgaria • Sofia, Bulgaria +35 more locations

PreviousPage 7 of 11Next

Other Conditions in Houston

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia